Accueil>>Signaling Pathways>> Others>>A-802715

A-802715

Catalog No.GC33419

A802715 est un dérivé de la méthylxanthine. A802715 a une TD50 (dose toxique de 50 %) de 0,9-1,1 mM.

Products are for research use only. Not for human use. We do not sell to patients.

A-802715 Chemical Structure

Cas No.: 107767-58-8

Taille Prix Stock Qté
1mg
184,00 $US
En stock
5mg
368,00 $US
En stock
10mg
625,00 $US
En stock
20mg
1 103,00 $US
En stock

Tel:(909) 407-4943 Email: sales@glpbio.com


Avis des clients

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Protocol Chemical Properties Product Documents Related Products

A802715 is a methylxanthine derivative. A802715 has a TD50 (toxic dose of 50%) of 0.9-1.1 mM.

The toxicity of the methylxanthine derivative A802715 is determined against the two human melanoma lines, Be11 and MeWo, and against the two human squamous cell carcinoma lines, 4197 and 4451, by vital dye staining assay. A802715 has a TD50 of 0.9-1.1 mM and is the most toxic. In p53 wt cells BrdU incorporations show that the irradiation-induced suppression of S-phase entry is strongly enhanced by A802715. A802715 prolongs the G2/M block or remain ineffective depending on the p53 status of the cell line[1].

[1]. Bohm L, et al. Influence of pentoxifylline, A-802710, propentofylline and A-802715 (Hoechst) on the expression of cell cycle blocks and S-phase content after irradiation damage. Biochim Biophys Acta. 2000 Dec 11;1499(1-2):1-10.

Avis

Review for A-802715

Average Rating: 5 ★★★★★ (Based on Reviews and 31 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for A-802715

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.